Fas ligand and TRAIL augment the effect of photodynamic therapy on the induction of apoptosis in JURKAT cells

被引:28
作者
Granville, DJ
Jiang, HJ
McManus, BM
Hunt, DWC
机构
[1] QLT Inc, Vancouver, BC V5T 4T5, Canada
[2] Univ British Columbia, St Pauls Hosp, iCAPTURE Ctr, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, McDonald Res Labs, Vancouver, BC V5Z 1M9, Canada
关键词
T lymphocytes; apoptosis; cytokine; cytotoxicity; Fas ligand; TRAIL; caspase;
D O I
10.1016/S1567-5769(01)00107-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and Fas ligand (FasL) trigger apoptosis by stimulating the formation of a death inducing signaling complex at the cytoplasmic terminus of their respective receptors. Photodynamic therapy (PDT) is an approved treatment for several types of cancer as well as for age-related macular degeneration and is under investigation for different cancer, ocular, autoimmune and cardiovascular indications. The effect of low dose PDT in combination with TRAIL and FasL on Jurkat lymphoma cell apoptosis was examined. Individually, TRAIL, FasL, and PDT could induce apoptosis in these cells. However, at suboptimal levels of PDT, the number of cells undergoing apoptosis was increased when recombinant FasL and/or TRAIL were added. Additive effects of these treatments were evident for different apoptosis parameters including DNA fragmentation, caspase processing and activity and caspase substrate degradation. Overall. these results provide evidence that PDT-treated cells may be more likely to undergo apoptosis when also exposed to receptor-mediated signals delivered by factors such as TRAIL or FasL. For PDT, immune cell-mediated death receptor ligation may represent a way whereby tumor cells that have withstood the direct effects of photosensitization may be eliminated. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1831 / 1840
页数:10
相关论文
共 56 条
[1]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[2]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[3]   POTENTIATION OF PHOTODYNAMIC THERAPY IN MICE WITH RECOMBINANT HUMAN TUMOR-NECROSIS-FACTOR-ALPHA [J].
BELLNIER, DA .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 1991, 8 (02) :203-210
[4]  
Carthy CM, 1999, LAB INVEST, V79, P953
[5]   Major DNA fragmentation is a late event in apoptosis [J].
Collins, JA ;
Schandl, CA ;
Young, KK ;
Vesely, J ;
Willingham, MC .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1997, 45 (07) :923-934
[6]   Foscan® (mTHPC) photosensitized macrophage activation:: enhancement of phagocytosis, nitric oxide release and tumour necrosis factor-α-mediated cytolytic activity [J].
Coutier, S ;
Bezdetnaya, L ;
Marchal, S ;
Melnikova, V ;
Belitchenko, I ;
Merlin, JL ;
Guillemin, F .
BRITISH JOURNAL OF CANCER, 1999, 81 (01) :37-42
[7]   FEATURES OF APOPTOTIC CELLS MEASURED BY FLOW-CYTOMETRY [J].
DARZYNKIEWICZ, Z ;
BRUNO, S ;
DELBINO, G ;
GORCZYCA, W ;
HOTZ, MA ;
LASSOTA, P ;
TRAGANOS, F .
CYTOMETRY, 1992, 13 (08) :795-808
[8]   Photodynamic therapy [J].
Dougherty, TJ ;
Gomer, CJ ;
Henderson, BW ;
Jori, G ;
Kessel, D ;
Korbelik, M ;
Moan, J ;
Peng, Q .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (12) :889-905
[9]  
Engbrecht BW, 1999, CANCER RES, V59, P4334
[10]  
Granville D J, 2000, Curr Opin Drug Discov Devel, V3, P232